PE20020485A1 - Derivados de quinolina y quinazolina como antagonistas del neuropeptido y - Google Patents
Derivados de quinolina y quinazolina como antagonistas del neuropeptido yInfo
- Publication number
- PE20020485A1 PE20020485A1 PE2001000891A PE2001000891A PE20020485A1 PE 20020485 A1 PE20020485 A1 PE 20020485A1 PE 2001000891 A PE2001000891 A PE 2001000891A PE 2001000891 A PE2001000891 A PE 2001000891A PE 20020485 A1 PE20020485 A1 PE 20020485A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- quinoline
- trifluoroalkyl
- quinazoline derivatives
- alcoxyl
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title abstract 4
- 239000005557 antagonist Substances 0.000 title abstract 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- -1 3-CHLORO-PHENYL Chemical class 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 229940086609 Lipase inhibitor Drugs 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical class [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 abstract 1
- 229960001243 orlistat Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A DERIVADOS DE QUINOLINA Y QUINAZOLINA DE FORMULA I DONDE R1 ES ALQUILO, CICLOALQUILO, ARALQUILO, TRIFLUOROALQUILO; R2 ES H, ALQUILO, ALCOXILO, HIDROXILO, HALOGENO, TRIFLUOROALQUILO, DIFLUOROALQUILO, TRIFLUOROALQUILO; R3 ES ARILO, HETEROARILO; R4 ES H, R5 ES H, ALQUILO, ARALQUILO; R6 Y R7 SON H, ALQUILO; A1 ES CH, N; A2 ES UN ANILLO HETEROCICLO DE 4-10 MIEMBROS SUSTITUIDO CON ALQUILO, OH, ALCOXILO, ALCOXIALQUILO, COOR5, CONR6R7, ENTRE OTROS; SON COMPUESTOS PREFERIDOS 7-(3-CLORO-FENIL)-2-METIL-4-PIRROLIDIN-1-IL-QUINOLINA; 2-METIL-4-PIRROLIDIN-1-IL-7-(3-TRIFLUOROMETIL-FENIL)-QUINOLINA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION Y AL USO CON UN INHIBIDOR DE LIPASAS COMO ORLISTAT. LOS COMPUESTOS SON ANTAGONISTAS DEL NEUROPEPTIDO Y; PUEDEN SER UTILES PARA EL TRATAMIENTO DE ARTRITIS, ENFERMEDADES CARDIOVASCULARES, DIABETES, INSUFICIENCIA RENAL, TRASTORNOS ALIMENTARIOS, OBESIDAD
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00119262 | 2000-09-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20020485A1 true PE20020485A1 (es) | 2002-06-14 |
Family
ID=8169763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2001000891A PE20020485A1 (es) | 2000-09-06 | 2001-09-05 | Derivados de quinolina y quinazolina como antagonistas del neuropeptido y |
Country Status (16)
Country | Link |
---|---|
US (2) | US6900226B2 (es) |
EP (1) | EP1318981A2 (es) |
JP (1) | JP2004508357A (es) |
KR (1) | KR100621272B1 (es) |
CN (1) | CN1274676C (es) |
AR (1) | AR030596A1 (es) |
AU (2) | AU1047402A (es) |
BR (1) | BR0113710A (es) |
CA (1) | CA2420703A1 (es) |
GT (1) | GT200100183A (es) |
MX (1) | MXPA03001928A (es) |
PA (1) | PA8528401A1 (es) |
PE (1) | PE20020485A1 (es) |
UY (1) | UY26926A1 (es) |
WO (1) | WO2002020488A2 (es) |
ZA (1) | ZA200301719B (es) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100621287B1 (ko) * | 2001-05-21 | 2006-09-13 | 에프. 호프만-라 로슈 아게 | 신경 펩타이드 y 수용체에 대한 리간드로서의 퀴놀린유도체 |
GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
NZ532427A (en) * | 2001-09-24 | 2008-07-31 | Imp Innovations Ltd | Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y) |
US6787558B2 (en) * | 2001-09-28 | 2004-09-07 | Hoffmann-La Roche Inc. | Quinoline derivatives |
US8058233B2 (en) * | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
EP1474145B1 (en) * | 2002-02-04 | 2008-04-23 | F. Hoffmann-La Roche Ag | Quinoline derivatives as npy antagonists |
EP1496838B1 (en) | 2002-03-12 | 2010-11-03 | Merck Sharp & Dohme Corp. | Substituted amides |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
KR100647932B1 (ko) | 2002-07-05 | 2006-11-23 | 에프. 호프만-라 로슈 아게 | 퀴나졸린 유도체 |
WO2004014884A1 (en) | 2002-08-07 | 2004-02-19 | F. Hoffmann-La Roche Ag | Thiazole derivatives |
EP1571146A4 (en) * | 2002-12-10 | 2010-09-01 | Ono Pharmaceutical Co | NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE |
US7166575B2 (en) * | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
GB0300571D0 (en) * | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
MXPA05009722A (es) * | 2003-03-10 | 2006-03-09 | Schering Corp | Inhibidores heterociclicos de cinasa: metodos de uso y sintesis. |
EP1608317B1 (en) * | 2003-03-25 | 2012-09-26 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7579357B2 (en) | 2003-08-13 | 2009-08-25 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
JP2007505121A (ja) | 2003-09-08 | 2007-03-08 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
JP4765627B2 (ja) | 2003-09-22 | 2011-09-07 | Msd株式会社 | 新規ピペリジン誘導体 |
CA2545340A1 (en) | 2003-11-10 | 2005-05-26 | Synta Pharmaceuticals, Corp. | Fused heterocyclic compounds |
CN102127057A (zh) | 2004-03-15 | 2011-07-20 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
US7718658B2 (en) * | 2004-09-02 | 2010-05-18 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
US8283354B2 (en) * | 2004-09-02 | 2012-10-09 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
KR100915481B1 (ko) * | 2004-11-09 | 2009-09-03 | 에프. 호프만-라 로슈 아게 | 아미노퀴나졸린 화합물 |
JP2008524331A (ja) | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
AU2006253312B2 (en) | 2005-05-30 | 2011-08-18 | Msd K.K. | Novel piperidine derivative |
GB0511986D0 (en) * | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
US20100216758A1 (en) | 2005-08-10 | 2010-08-26 | Makoto Ando | Pyridone Compounds |
CA2619770A1 (en) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridone derivative |
WO2007029847A1 (ja) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | 二環性芳香族置換ピリドン誘導体 |
ZA200802857B (en) | 2005-09-14 | 2009-09-30 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors for treating diabetes |
KR101368988B1 (ko) | 2005-09-16 | 2014-02-28 | 다케다 야쿠힌 고교 가부시키가이샤 | 디펩티딜 펩티다제 억제제 |
CN101291662A (zh) | 2005-10-21 | 2008-10-22 | 诺瓦提斯公司 | 肾素抑制剂和抗血脂异常剂和/或抗肥胖剂的组合 |
JPWO2007049798A1 (ja) | 2005-10-27 | 2009-04-30 | 萬有製薬株式会社 | 新規ベンゾオキサチイン誘導体 |
AU2006312557B2 (en) | 2005-11-10 | 2011-12-08 | Msd K.K. | Aza-substituted spiro derivative |
US7678803B2 (en) * | 2006-08-24 | 2010-03-16 | Serenex, Inc. | Quinazoline derivatives for the treatment of cancer |
US8027888B2 (en) * | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
CA2664358A1 (en) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diarylketimine derivative |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
TWI428346B (zh) * | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
EP2145884B1 (en) | 2007-04-02 | 2014-08-06 | Msd K.K. | Indoledione derivative |
PE20090717A1 (es) * | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US20100120694A1 (en) | 2008-06-04 | 2010-05-13 | Synergy Pharmaceuticals, Inc. | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders |
JPWO2009110510A1 (ja) | 2008-03-06 | 2011-07-14 | Msd株式会社 | アルキルアミノピリジン誘導体 |
JPWO2009119726A1 (ja) | 2008-03-28 | 2011-07-28 | Msd株式会社 | メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体 |
US20110071129A1 (en) | 2008-06-19 | 2011-03-24 | Makoto Ando | Spirodiamine-diaryl ketoxime derivative |
EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2010013595A1 (ja) | 2008-07-30 | 2010-02-04 | 萬有製薬株式会社 | 5員-5員又は5員-6員縮環シクロアルキルアミン誘導体 |
EP2348018A4 (en) | 2008-09-25 | 2012-04-25 | Kyorin Seiyaku Kk | HETEROCYCLIC BIARYLIC DERIVATIVE AND PDE INHIBITOR COMPRISING THE SAME AS ACTIVE INGREDIENT |
US20110224250A1 (en) * | 2008-10-09 | 2011-09-15 | Yasushi Kohno | Isoquinoline derivative, and pde inhibitor comprising same as active ingredient |
EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US20110230399A1 (en) * | 2008-11-25 | 2011-09-22 | Bowen Richard L | Methods for Treating Obesity Related Disease |
US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
MX348131B (es) | 2011-02-25 | 2017-05-26 | Merck Sharp & Dohme | Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos. |
JP6170060B2 (ja) | 2011-11-04 | 2017-07-26 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 新規アリール−キノリン誘導体 |
US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
KR101415806B1 (ko) | 2012-08-22 | 2014-07-09 | 한국화학연구원 | 퀴놀린 유도체를 포함하는 골 질환의 예방 또는 치료용 약학적 조성물 |
US9840512B2 (en) | 2013-02-22 | 2017-12-12 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
BR112015030326A2 (pt) | 2013-06-05 | 2017-08-29 | Synergy Pharmaceuticals Inc | Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
ES2901114T3 (es) | 2014-08-29 | 2022-03-21 | Tes Pharma S R L | Inhibidores de ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa |
US9353093B2 (en) | 2014-10-07 | 2016-05-31 | Allergan, Inc. | Indole-1-carboxamides as kinase inhibitors |
KR20190065312A (ko) | 2016-10-14 | 2019-06-11 | 테스 파마 에스.알.엘. | 알파-아미노-베타-카복시뮤콘산 세미알데하이드 데카복실라제의 저해제 |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
WO2020104456A1 (en) | 2018-11-20 | 2020-05-28 | Tes Pharma S.R.L | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE |
CN109897874A (zh) * | 2019-03-25 | 2019-06-18 | 苏州同力生物医药有限公司 | 一种制备手性异喹啉羧酸的方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4012513A (en) * | 1971-11-03 | 1977-03-15 | Imperial Chemical Industries Limited | Indole derivatives for providing analgesic and anti-inflammatory effects |
CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
WO1986006721A1 (en) | 1985-05-07 | 1986-11-20 | Alkaloida Vegyészeti Gyár | Triazolyl quinoline derivatives |
CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
ES2074867T3 (es) * | 1990-11-06 | 1995-09-16 | Pfizer | Derivados de quinazolina para potenciar la actividad antitumoral. |
US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
KR0144833B1 (ko) * | 1992-12-28 | 1998-07-15 | 김태훈 | 신규의 퀴나졸린 유도체 및 그의 제조방법 |
CA2118117A1 (en) * | 1993-02-18 | 1994-08-19 | Shigeki Fujiwara | Adenosine uptake inhibitor |
IL120724A0 (en) | 1995-09-01 | 1997-08-14 | Lilly Co Eli | Indolyl neuropeptide Y receptor antagonists |
US6004996A (en) | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
WO2000009123A1 (en) | 1998-08-14 | 2000-02-24 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions containing lipase inhibitors and chitosan |
FR2795726A1 (fr) | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
AR028782A1 (es) * | 2000-07-05 | 2003-05-21 | Taisho Pharmaceutical Co Ltd | Derivados heterociclicos tetrahidropiridino o piperidino |
BRPI0113146B8 (pt) | 2000-08-10 | 2021-05-25 | Mitsubishi Pharma Corp | "derivados de prolina e composição farmacêutica que os compreende". |
US6576644B2 (en) * | 2000-09-06 | 2003-06-10 | Bristol-Myers Squibb Co. | Quinoline inhibitors of cGMP phosphodiesterase |
SE0004054D0 (sv) * | 2000-11-06 | 2000-11-06 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
KR100621287B1 (ko) * | 2001-05-21 | 2006-09-13 | 에프. 호프만-라 로슈 아게 | 신경 펩타이드 y 수용체에 대한 리간드로서의 퀴놀린유도체 |
US6787558B2 (en) * | 2001-09-28 | 2004-09-07 | Hoffmann-La Roche Inc. | Quinoline derivatives |
EP1474145B1 (en) * | 2002-02-04 | 2008-04-23 | F. Hoffmann-La Roche Ag | Quinoline derivatives as npy antagonists |
EP1534681A1 (en) * | 2002-06-27 | 2005-06-01 | Schering Aktiengesellschaft | Substituted quinoline ccr5 receptor antagonists |
KR100647932B1 (ko) * | 2002-07-05 | 2006-11-23 | 에프. 호프만-라 로슈 아게 | 퀴나졸린 유도체 |
-
2001
- 2001-08-27 US US09/939,883 patent/US6900226B2/en not_active Expired - Fee Related
- 2001-08-30 WO PCT/EP2001/010014 patent/WO2002020488A2/en not_active Application Discontinuation
- 2001-08-30 AU AU1047402A patent/AU1047402A/xx active Pending
- 2001-08-30 CN CNB018134610A patent/CN1274676C/zh not_active Expired - Fee Related
- 2001-08-30 KR KR1020037003252A patent/KR100621272B1/ko not_active IP Right Cessation
- 2001-08-30 JP JP2002525110A patent/JP2004508357A/ja active Pending
- 2001-08-30 AU AU2002210474A patent/AU2002210474B2/en not_active Ceased
- 2001-08-30 MX MXPA03001928A patent/MXPA03001928A/es not_active Application Discontinuation
- 2001-08-30 CA CA002420703A patent/CA2420703A1/en not_active Abandoned
- 2001-08-30 EP EP01978324A patent/EP1318981A2/en not_active Withdrawn
- 2001-08-30 BR BR0113710-7A patent/BR0113710A/pt not_active IP Right Cessation
- 2001-09-04 AR ARP010104191A patent/AR030596A1/es unknown
- 2001-09-04 PA PA20018528401A patent/PA8528401A1/es unknown
- 2001-09-05 GT GT200100183A patent/GT200100183A/es unknown
- 2001-09-05 UY UY26926A patent/UY26926A1/es not_active Application Discontinuation
- 2001-09-05 PE PE2001000891A patent/PE20020485A1/es not_active Application Discontinuation
-
2003
- 2003-02-28 ZA ZA200301719A patent/ZA200301719B/en unknown
-
2005
- 2005-04-07 US US11/100,938 patent/US7265125B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2002020488A2 (en) | 2002-03-14 |
KR100621272B1 (ko) | 2006-09-13 |
US20050176698A1 (en) | 2005-08-11 |
US6900226B2 (en) | 2005-05-31 |
UY26926A1 (es) | 2002-03-22 |
AU2002210474B2 (en) | 2006-11-02 |
ZA200301719B (en) | 2004-06-22 |
WO2002020488A3 (en) | 2002-05-16 |
CA2420703A1 (en) | 2002-03-14 |
KR20030027110A (ko) | 2003-04-03 |
JP2004508357A (ja) | 2004-03-18 |
BR0113710A (pt) | 2003-06-03 |
AR030596A1 (es) | 2003-08-27 |
PA8528401A1 (es) | 2002-09-30 |
US20020052356A1 (en) | 2002-05-02 |
CN1444563A (zh) | 2003-09-24 |
GT200100183A (es) | 2002-05-23 |
EP1318981A2 (en) | 2003-06-18 |
CN1274676C (zh) | 2006-09-13 |
US7265125B2 (en) | 2007-09-04 |
MXPA03001928A (es) | 2003-06-19 |
AU1047402A (en) | 2002-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20020485A1 (es) | Derivados de quinolina y quinazolina como antagonistas del neuropeptido y | |
PE20020667A1 (es) | Derivados de piperazina como ligandos del receptor 5ht2 | |
PE20091068A1 (es) | Compuestos pirrolo[3,2-d]pirimidina y su uso como inhibidores de quinasa pi3 y quinasa mtor | |
PE20020616A1 (es) | Compuestos de piperidina como antagonistas del receptor ccr-3 | |
EA199900693A1 (ru) | Атропизомеры 3-арил-4(3h)-хиназолинонов и их использование в качестве антагонистов амра-рецепторов | |
PE20010758A1 (es) | DERIVADOS DE DIHIDROPIRIMIDO[4,5-d]PIRIMIDONA SUSTITUIDOS POR HETEROALQUILO COMO INHIBIDORES DE QUINASAS p38 | |
EA200300829A1 (ru) | Производные 1-арил- или 1-алкилсульфонилбензазола в качестве лигандов 5-гидрокситриптамина-6 | |
PE20030746A1 (es) | DERIVADOS DE PIRIDO [2,1-a] ISOQUINOLINA | |
PE20040593A1 (es) | DERIVADOS DE DIHIDROPIRIMIDO[4,5-d]PIRIMIDONA AMINO SUSTITUIDOS COMO INHIBIDORES DE TIROSINACINASAS DEL GRUPO SRC | |
DE60035496D1 (de) | Indolinderivate als progesteron antagonisten | |
PE20040935A1 (es) | Analogos de 2-quinazolina sustituida-4-ilamina como moduladores de los receptores de capsaicina | |
PE20030131A1 (es) | Derivados de 6-fenildihidropirrolpirimidindiona | |
PE20060600A1 (es) | Derivados de aminopiridina como inhibidores selectivos de la aurora a quinasa | |
AR027402A1 (es) | Derivados de pirimidina. | |
EA200300619A1 (ru) | Серотонинергические средства | |
PE20090718A1 (es) | Derivados de espiroindolinona | |
PE20050664A1 (es) | Derivados de 1h-imidazo[4,5-c]quinolina | |
PE20061093A1 (es) | Piperazinas sustituidas con heterociclos con actividad antagonista de cxcr3 | |
PE20060243A1 (es) | Derivados de 4-amino insustituido-5-(4-urea-fenil)-pirrolotriazina | |
AR040626A1 (es) | Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy) | |
EA200700141A1 (ru) | Новые аминоциклические производные мочевины, их получение и фармацевтическое применение в качестве ингибиторов киназы | |
PE20070004A1 (es) | Imidazoquinolinas como inhibidores de quinasa de lipido | |
PE20061303A1 (es) | Composicion farmaceutica que comprende oxaprozina | |
PE20051171A1 (es) | Inhibidores de proteina quinasas con estructura de 3-quinolincarbonitrilo | |
AR051767A1 (es) | Derivados de quinolina e isoquinolina 5-sustituidos un procedimiento para su preparacion y su uso como inhibidores de la inflamacion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |